JP2019536805A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019536805A5 JP2019536805A5 JP2019530011A JP2019530011A JP2019536805A5 JP 2019536805 A5 JP2019536805 A5 JP 2019536805A5 JP 2019530011 A JP2019530011 A JP 2019530011A JP 2019530011 A JP2019530011 A JP 2019530011A JP 2019536805 A5 JP2019536805 A5 JP 2019536805A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- inhibitor
- administered
- cdk4
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 68
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 claims 26
- 239000002246 antineoplastic agent Substances 0.000 claims 26
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 25
- 229960004562 carboplatin Drugs 0.000 claims 25
- 229960005420 etoposide Drugs 0.000 claims 24
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 24
- 229940127089 cytotoxic agent Drugs 0.000 claims 23
- 206010006187 Breast cancer Diseases 0.000 claims 12
- 208000026310 Breast neoplasm Diseases 0.000 claims 12
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 12
- 229960003852 atezolizumab Drugs 0.000 claims 12
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims 12
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 11
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 11
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 11
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 11
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 11
- 238000011282 treatment Methods 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 10
- 238000012423 maintenance Methods 0.000 claims 9
- 206010041067 Small cell lung cancer Diseases 0.000 claims 7
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 7
- 229930012538 Paclitaxel Natural products 0.000 claims 6
- 229960004679 doxorubicin Drugs 0.000 claims 6
- 230000006698 induction Effects 0.000 claims 6
- 229960001592 paclitaxel Drugs 0.000 claims 6
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 6
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 claims 4
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims 4
- 239000012270 PD-1 inhibitor Substances 0.000 claims 4
- 239000012668 PD-1-inhibitor Substances 0.000 claims 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 4
- 229960004316 cisplatin Drugs 0.000 claims 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 3
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 3
- 229940044683 chemotherapy drug Drugs 0.000 claims 3
- 229960004397 cyclophosphamide Drugs 0.000 claims 3
- 229960002949 fluorouracil Drugs 0.000 claims 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 3
- 229960005277 gemcitabine Drugs 0.000 claims 3
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 3
- 229960001756 oxaliplatin Drugs 0.000 claims 3
- 238000011287 therapeutic dose Methods 0.000 claims 3
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 3
- 102000003903 Cyclin-dependent kinases Human genes 0.000 claims 2
- 108090000266 Cyclin-dependent kinases Proteins 0.000 claims 2
- 229950002916 avelumab Drugs 0.000 claims 2
- 229950009791 durvalumab Drugs 0.000 claims 2
- 102000015694 estrogen receptors Human genes 0.000 claims 2
- 108010038795 estrogen receptors Proteins 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229960002621 pembrolizumab Drugs 0.000 claims 2
- 230000010076 replication Effects 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000011269 treatment regimen Methods 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022091214A JP7483791B2 (ja) | 2016-12-05 | 2022-06-03 | 化学療法計画中の免疫応答の保護 |
| JP2023143202A JP7710496B2 (ja) | 2016-12-05 | 2023-09-04 | 化学療法計画中の免疫応答の保護 |
| JP2025115144A JP2025148426A (ja) | 2016-12-05 | 2025-07-08 | 化学療法計画中の免疫応答の保護 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662430302P | 2016-12-05 | 2016-12-05 | |
| US62/430,302 | 2016-12-05 | ||
| US201762479605P | 2017-03-31 | 2017-03-31 | |
| US62/479,605 | 2017-03-31 | ||
| PCT/US2017/064775 WO2018106729A1 (en) | 2016-12-05 | 2017-12-05 | Preservation of immune response during chemotherapy regimens |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022091214A Division JP7483791B2 (ja) | 2016-12-05 | 2022-06-03 | 化学療法計画中の免疫応答の保護 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019536805A JP2019536805A (ja) | 2019-12-19 |
| JP2019536805A5 true JP2019536805A5 (enExample) | 2021-01-21 |
Family
ID=62491342
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019530011A Pending JP2019536805A (ja) | 2016-12-05 | 2017-12-05 | 化学療法計画中の免疫応答の保護 |
| JP2022091214A Active JP7483791B2 (ja) | 2016-12-05 | 2022-06-03 | 化学療法計画中の免疫応答の保護 |
| JP2023143202A Active JP7710496B2 (ja) | 2016-12-05 | 2023-09-04 | 化学療法計画中の免疫応答の保護 |
| JP2025115144A Pending JP2025148426A (ja) | 2016-12-05 | 2025-07-08 | 化学療法計画中の免疫応答の保護 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022091214A Active JP7483791B2 (ja) | 2016-12-05 | 2022-06-03 | 化学療法計画中の免疫応答の保護 |
| JP2023143202A Active JP7710496B2 (ja) | 2016-12-05 | 2023-09-04 | 化学療法計画中の免疫応答の保護 |
| JP2025115144A Pending JP2025148426A (ja) | 2016-12-05 | 2025-07-08 | 化学療法計画中の免疫応答の保護 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11529352B2 (enExample) |
| EP (1) | EP3548030A4 (enExample) |
| JP (4) | JP2019536805A (enExample) |
| KR (4) | KR20240024296A (enExample) |
| CN (3) | CN117562905A (enExample) |
| AU (4) | AU2017372856B9 (enExample) |
| BR (1) | BR112019011410A2 (enExample) |
| CA (1) | CA3045465A1 (enExample) |
| IL (4) | IL311265A (enExample) |
| MX (2) | MX2019006523A (enExample) |
| NZ (2) | NZ795224A (enExample) |
| WO (1) | WO2018106729A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014144847A2 (en) * | 2013-03-15 | 2014-09-18 | G1 Therapeutics, Inc. | Hspc-sparing treatments for rb-positive abnormal cellular proliferation |
| ES2836772T3 (es) | 2014-04-30 | 2021-06-28 | Fujifilm Corp | Composición liposomal y método para producirla |
| CN106397592A (zh) * | 2015-07-31 | 2017-02-15 | 苏州康宁杰瑞生物科技有限公司 | 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白 |
| WO2018005863A1 (en) * | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
| CA3045465A1 (en) | 2016-12-05 | 2018-06-14 | G1 Therapeutics, Inc. | Preservation of immune response during chemotherapy regimens |
| MX2019008158A (es) | 2017-01-06 | 2019-12-09 | G1 Therapeutics Inc | Terapia de combinacion para el tratamiento del cancer. |
| US11395821B2 (en) | 2017-01-30 | 2022-07-26 | G1 Therapeutics, Inc. | Treatment of EGFR-driven cancer with fewer side effects |
| KR102328463B1 (ko) | 2017-03-31 | 2021-11-17 | 후지필름 가부시키가이샤 | 리포솜 조성물 및 의약 조성물 |
| WO2019054865A1 (en) * | 2017-09-14 | 2019-03-21 | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) | T-cell based immunotherapy |
| US20200377599A1 (en) * | 2017-11-30 | 2020-12-03 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for treating cancer |
| JP2021509680A (ja) | 2018-01-08 | 2021-04-01 | ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | Ｇ１ｔ３８の優れた投与レジメン |
| AU2019253706A1 (en) * | 2018-04-09 | 2020-11-26 | G1 Therapeutics, Inc. | Treatment of cancers having driving oncogenic mutations |
| CN112312895B (zh) * | 2018-06-20 | 2023-05-09 | 富士胶片株式会社 | 包含内含药物的脂质体组合物及免疫检查点抑制剂的组合医药 |
| WO2019244978A1 (ja) * | 2018-06-20 | 2019-12-26 | 富士フイルム株式会社 | ゲムシタビンを内包するリポソーム組成物および免疫チェックポイント阻害剤を含む組合せ医薬 |
| EP3853251A1 (en) * | 2018-09-19 | 2021-07-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy |
| EP3861987A4 (en) | 2018-10-01 | 2021-09-15 | FUJIFILM Corporation | COMBINATION DRUG CONTAINING A LIPOSOME COMPOSITION ENCAPSULATING A DRUG AND A PLATINUM PREPARATION |
| WO2020097625A1 (en) * | 2018-11-09 | 2020-05-14 | G1 Therapeutics, Inc. | Therapeutic regimens for treatment of cancer using eribulin and selective cdk4/6 inhibitor combinations |
| WO2020219926A1 (en) * | 2019-04-24 | 2020-10-29 | The Trustees Of The University Of Pennsylvania | Treatment of cancer with cdk inhibitors |
| TWI879768B (zh) * | 2019-05-03 | 2025-04-11 | 美商建南德克公司 | 用抗pd-l1抗體治療癌症之方法 |
| TW202114684A (zh) * | 2019-06-18 | 2021-04-16 | 美商G1治療公司 | 增強癌症病患之抗腫瘤免疫之方法 |
| US12270949B2 (en) | 2019-11-12 | 2025-04-08 | Pointcloud Inc. | Dual path light detection and ranging system |
| WO2021110122A1 (zh) * | 2019-12-05 | 2021-06-10 | 基石药业（苏州）有限公司 | Cdk4/6抑制剂的组合疗法 |
| EP4652997A2 (en) | 2020-05-19 | 2025-11-26 | Pharmacosmos Holding A/s | Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
| CN116157403B (zh) * | 2020-06-15 | 2025-04-25 | 海南先声再明医药股份有限公司 | 曲拉西利的形态及其制造方法 |
| TW202231283A (zh) * | 2020-10-19 | 2022-08-16 | 美商G1治療公司 | 用於治療轉移性大腸直腸癌之經改良之基於氟尿嘧啶之多藥劑化學治療 |
| EP4255576A4 (en) * | 2020-12-07 | 2024-10-23 | The Trustees of Indiana University | METHODS FOR SENSITIZING CANCER CELLS TO IMMUNE ATTACK USING ATRACTYLENOLIDE I |
| CN113788837B (zh) * | 2021-08-02 | 2022-08-26 | 深圳湾实验室坪山生物医药研发转化中心 | Trilaciclib的合成方法 |
| WO2023068220A1 (ja) * | 2021-10-18 | 2023-04-27 | 株式会社Preferred Networks | 予測方法及びバイオマーカー |
| EP4482522A2 (en) * | 2022-02-25 | 2025-01-01 | Lanier Biotherapeutics, Inc. | Anti-alarmin binding molecules and treatment of pneumonitis |
| CN119816315A (zh) * | 2022-09-02 | 2025-04-11 | Rs肿瘤学有限责任公司 | 硫链丝菌素给药方案 |
| WO2024216208A2 (en) * | 2023-04-14 | 2024-10-17 | Concarlo Therapeutics, Inc. | Brk peptides and methods of use |
| WO2024238476A2 (en) * | 2023-05-15 | 2024-11-21 | Cedars-Sinai Medical Center | Y chromosome gene signature as a target for cancer therapy in combination with immunotherapy |
| CN117511855B (zh) * | 2023-11-09 | 2024-11-19 | 南京医科大学 | Epha抑制剂在诱导减数分裂中的应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0327380D0 (en) | 2003-11-25 | 2003-12-31 | Cyclacel Ltd | Method |
| CN101415409B (zh) | 2006-04-05 | 2012-12-05 | 诺瓦提斯公司 | 用于治疗癌症的治疗剂的组合 |
| KR20090091306A (ko) | 2006-12-22 | 2009-08-27 | 노파르티스 아게 | 암, 염증 및 바이러스 감염 치료용 ｃｄｋ 억제제로서의 헤테로아릴-헤테로아릴 화합물 |
| US9259399B2 (en) | 2007-11-07 | 2016-02-16 | Cornell University | Targeting CDK4 and CDK6 in cancer therapy |
| JP5579715B2 (ja) | 2008-07-29 | 2014-08-27 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | ｃｄｋ阻害剤および抗悪性腫瘍剤を含む治療用組合せ |
| US8685980B2 (en) | 2008-08-22 | 2014-04-01 | Novartis Ag | Pyrrolopyrimidine compounds and their uses |
| CA2738925A1 (en) | 2008-10-01 | 2010-04-08 | The University Of North Carolina At Chapel Hill | Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors |
| WO2010051127A2 (en) | 2008-10-01 | 2010-05-06 | The University Of North Carolina At Chapel Hill | Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors |
| WO2010132725A2 (en) | 2009-05-13 | 2010-11-18 | The University Of North Carolina At Chapel Hill | Cyclin dependent kinase inhibitors and methods of use |
| US8691830B2 (en) | 2010-10-25 | 2014-04-08 | G1 Therapeutics, Inc. | CDK inhibitors |
| EP2632467B1 (en) | 2010-10-25 | 2016-06-22 | G1 Therapeutics, Inc. | Cdk inhibitors |
| BR112013033940A2 (pt) | 2011-07-01 | 2017-02-14 | Novartis Ag | terapia combinada compreendendo um inibidor de cdk4/6 e um inibidor de pi3k para uso no tratamento de câncer |
| EP3216792B1 (en) | 2012-03-29 | 2020-05-27 | G1 Therapeutics, Inc. | Lactam kinase inhibitors |
| CN104302620A (zh) | 2012-04-26 | 2015-01-21 | 弗朗西斯·泽维尔·塔瓦雷斯 | 内酰胺的合成 |
| WO2014144847A2 (en) | 2013-03-15 | 2014-09-18 | G1 Therapeutics, Inc. | Hspc-sparing treatments for rb-positive abnormal cellular proliferation |
| CN105407723A (zh) | 2013-03-15 | 2016-03-16 | G1治疗公司 | 高效的抗赘生剂和抗增生剂 |
| US20140274896A1 (en) | 2013-03-15 | 2014-09-18 | G1 Therapeutics, Inc. | Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation |
| BR112015025711A8 (pt) | 2013-04-08 | 2019-12-17 | Janssen Pharmaceutica Nv | uso de ibrutinibe e coposição farmacêutica compreendendo ibrutinibe e um agente anticâncer |
| JP2016531907A (ja) * | 2013-08-02 | 2016-10-13 | アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップＡｄｕｒｏ Ｂｉｏｔｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｅｕｒｏｐｅ Ｂ．Ｖ． | 免疫刺激のためのｃｄ２７アゴニストと免疫チェックポイント阻害との組み合わせ |
| US20160257688A1 (en) | 2013-10-24 | 2016-09-08 | Francis Xavier Tavares | Process for Synthesis of Lactams |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| WO2015161285A1 (en) | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic lactams for use in the protection of hematopoietic stem and progenitor cells against ionizing radiation |
| CN106714839A (zh) | 2014-05-15 | 2017-05-24 | 百时美施贵宝公司 | 使用抗pd‑1抗体和另一种抗癌剂的组合治疗肺癌 |
| WO2016040848A1 (en) * | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
| EP3191098A4 (en) | 2014-09-12 | 2018-04-25 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
| KR20170060042A (ko) | 2014-09-13 | 2017-05-31 | 노파르티스 아게 | Alk 억제제의 조합 요법 |
| KR20170066546A (ko) | 2014-10-03 | 2017-06-14 | 노파르티스 아게 | 조합 요법 |
| RU2726996C1 (ru) * | 2014-12-16 | 2020-07-17 | Бристол-Маерс Сквибб Компани | Применение ингибиторов иммунных контрольных точек при новообразованиях центральной нервной системы |
| US20160220569A1 (en) | 2015-02-03 | 2016-08-04 | G1 Therapeutics, Inc. | CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy |
| EP3471717A4 (en) | 2016-06-20 | 2020-01-22 | Kura Oncology, Inc. | TREATMENT OF PLATE CELL CARCINOMAS WITH ERK INHIBITORS |
| EP3538148A1 (en) | 2016-11-08 | 2019-09-18 | Dana-Farber Cancer Institute | Compositions and methods of modulating anti-tumor immunity |
| US20190275049A1 (en) | 2016-11-16 | 2019-09-12 | Pfizer Inc. | Combination of an EGFR T790M Inhibitor and a CDK Inhibitor for the Treatment of Non-Small Cell Lung Cancer |
| CA3043288A1 (en) | 2016-11-30 | 2018-06-07 | Oncotyrol Center For Personalized Cancer Medicine Gmbh | 3-amino-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-ones as cyclin dependent kinase inhibitors |
| CA3045465A1 (en) | 2016-12-05 | 2018-06-14 | G1 Therapeutics, Inc. | Preservation of immune response during chemotherapy regimens |
| WO2018183479A1 (en) | 2017-03-30 | 2018-10-04 | Dana-Farber Cancer Institute, Inc. | Methods for modulating regulatory t cells and immune responses using cdk4/6 inhibitors |
| US20200377599A1 (en) | 2017-11-30 | 2020-12-03 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for treating cancer |
-
2017
- 2017-12-05 CA CA3045465A patent/CA3045465A1/en active Pending
- 2017-12-05 CN CN202311165820.1A patent/CN117562905A/zh active Pending
- 2017-12-05 AU AU2017372856A patent/AU2017372856B9/en active Active
- 2017-12-05 EP EP17878506.9A patent/EP3548030A4/en active Pending
- 2017-12-05 MX MX2019006523A patent/MX2019006523A/es unknown
- 2017-12-05 CN CN202311165935.0A patent/CN117530948A/zh active Pending
- 2017-12-05 JP JP2019530011A patent/JP2019536805A/ja active Pending
- 2017-12-05 NZ NZ795224A patent/NZ795224A/en unknown
- 2017-12-05 BR BR112019011410-6A patent/BR112019011410A2/pt not_active Application Discontinuation
- 2017-12-05 IL IL311265A patent/IL311265A/en unknown
- 2017-12-05 NZ NZ753631A patent/NZ753631A/en unknown
- 2017-12-05 CN CN201780075215.1A patent/CN110035759A/zh active Pending
- 2017-12-05 WO PCT/US2017/064775 patent/WO2018106729A1/en not_active Ceased
- 2017-12-05 KR KR1020247004112A patent/KR20240024296A/ko active Pending
- 2017-12-05 IL IL317919A patent/IL317919A/en unknown
- 2017-12-05 KR KR1020247004108A patent/KR20240023676A/ko active Pending
- 2017-12-05 KR KR1020247004113A patent/KR20240023677A/ko not_active Withdrawn
- 2017-12-05 KR KR1020197019110A patent/KR20190092478A/ko not_active Ceased
- 2017-12-05 IL IL303038A patent/IL303038B2/en unknown
-
2019
- 2019-05-26 IL IL266870A patent/IL266870A/en unknown
- 2019-06-04 MX MX2023006991A patent/MX2023006991A/es unknown
- 2019-06-05 US US16/432,244 patent/US11529352B2/en active Active
-
2022
- 2022-06-03 JP JP2022091214A patent/JP7483791B2/ja active Active
-
2023
- 2023-09-04 JP JP2023143202A patent/JP7710496B2/ja active Active
- 2023-12-11 AU AU2023282168A patent/AU2023282168B2/en active Active
- 2023-12-11 AU AU2023282170A patent/AU2023282170B2/en active Active
-
2025
- 2025-07-08 JP JP2025115144A patent/JP2025148426A/ja active Pending
- 2025-10-01 AU AU2025242155A patent/AU2025242155A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019536805A5 (enExample) | ||
| US20230404999A1 (en) | Combination therapy with an antitumor alkaloid | |
| Laderian et al. | CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib | |
| JP2018508516A5 (enExample) | ||
| JP2024015120A5 (enExample) | ||
| JP2012506448A5 (enExample) | ||
| JP2017516802A5 (enExample) | ||
| JP2012180381A5 (enExample) | ||
| JP2010514787A5 (enExample) | ||
| Pincus et al. | Clinical trials documenting the efficacy of low-dose glucocorticoids in rheumatoid arthritis | |
| HRP20201737T1 (hr) | Metoda za liječenje tumora, farmaceutski sastav i pribor za lijekove | |
| JP2014513089A5 (enExample) | ||
| IL320452A (en) | Combination therapy for prostate cancer | |
| JP2011529968A5 (enExample) | ||
| JP2019530706A5 (enExample) | ||
| JP2018503610A5 (enExample) | ||
| RU2016151303A (ru) | Применение эрибулина в лечении рака | |
| JP2019508476A5 (enExample) | ||
| JP2016515586A5 (enExample) | ||
| JP2018530578A5 (enExample) | ||
| JP2019517498A5 (enExample) | ||
| JP2014511383A5 (enExample) | ||
| Lee et al. | S-1 based doublet as an adjuvant chemotherapy for curatively resected stage III gastric cancer: results from the randomized phase III POST trial | |
| JP2004535441A5 (enExample) | ||
| CN102438608A (zh) | 包含ave8062和索拉非尼的抗肿瘤组合 |